← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
RACE
Ferrari N.V.
Valuation N/A
Consumer Cyclical Risk 50 · Elevated
Price$413.78
Model IV—
P/IV—
Limited data — see page
RADX
Radiopharm Theranostics Ltd
Valuation N/A
Healthcare Risk 26 · Moderate
Price$1.98
Model IV—
P/IV—
Limited data — see page
RAIN
Rain Enhancement Technologies Holdco, Inc.
Valuation N/A
Industrials
Price$0.74
Model IV—
P/IV—
Limited data — see page
RAINW
Rain Enhancement Technologies Holdco, Inc.
Valuation N/A
Industrials
Price$0.16
Model IV—
P/IV—
Limited data — see page
RANG
Range Capital Acquisition Corp.
Valuation N/A
Financial Services Risk 27 · Moderate
Price$10.81
Model IV—
P/IV—
Limited data — see page
RANGR
Range Capital Acquisition Corp.
Valuation N/A
Financial Services Risk 43 · Elevated
Price$0.28
Model IV—
P/IV—
Limited data — see page
RANGU
Range Capital Acquisition Corp.
Valuation N/A
Financial Services Risk 42 · Elevated
Price$11.32
Model IV—
P/IV—
Limited data — see page
RAPP
Rapport Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$43.62
Model IV—
P/IV—
Limited data — see page
RAYA
Erayak Power Solution Group Inc.
Valuation N/A
Technology Risk 44 · Elevated
Price$2.15
Model IV—
P/IV—
Limited data — see page
RBNE
Robin Energy Ltd.
Valuation N/A
Industrials Risk 43 · Elevated
Price$2.66
Model IV—
P/IV—
Market implies -50.0%/yr vs model -8.4% · below model
RCAT
Red Cat Holdings, Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$7.80
Model IV—
P/IV—
Market implies +32.1%/yr vs model +50.0% · below model
RCG
RENN Fund, Inc.
Valuation N/A
Unknown
Price$3.04
Model IV—
P/IV—
Limited data — see page
RCI
ROGERS COMMUNICATIONS INC
Valuation N/A
Communication Services
Price$35.84
Model IV—
P/IV—
Limited data — see page
RCKT
ROCKET PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$3.35
Model IV—
P/IV—
Limited data — see page
RCKTW
ROCKET PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$0.00
Model IV—
P/IV—
Limited data — see page
RCS
PIMCO STRATEGIC INCOME FUND, INC.
Valuation N/A
Unknown
Price$4.90
Model IV—
P/IV—
Limited data — see page
RCUS
Arcus Biosciences, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$24.59
Model IV—
P/IV—
Market implies +101.2%/yr vs model +2.0% · above model
RDAC
Rising Dragon Acquisition Corp.
Valuation N/A
Financial Services Risk 34 · Moderate
Price$5.29
Model IV—
P/IV—
Limited data — see page
RDACR
Rising Dragon Acquisition Corp.
Valuation N/A
Financial Services Risk 33 · Moderate
Price$0.10
Model IV—
P/IV—
Limited data — see page
RDACU
Rising Dragon Acquisition Corp.
Valuation N/A
Financial Services Risk 42 · Elevated
Price$9.95
Model IV—
P/IV—
Limited data — see page
RDAG
Republic Digital Acquisition Co
Valuation N/A
Financial Services
Price$10.43
Model IV—
P/IV—
Limited data — see page
RDAGU
Republic Digital Acquisition Co
Valuation N/A
Financial Services
Price$10.51
Model IV—
P/IV—
Limited data — see page
RDAGW
Republic Digital Acquisition Co
Valuation N/A
Financial Services
Price$0.28
Model IV—
P/IV—
Limited data — see page
RDHL
RedHill Biopharma Ltd.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$0.64
Model IV—
P/IV—
Limited data — see page
RDI
READING INTERNATIONAL INC
Valuation N/A
Communication Services Risk 34 · Moderate
Price$2.17
Model IV—
P/IV—
Market implies -50.0%/yr vs model +9.9% · below model
RDW
Redwire Corp
Valuation N/A
Consumer Cyclical Risk 34 · Moderate
Price$10.62
Model IV—
P/IV—
Market implies +83.9%/yr vs model +8.0% · above model
RDY
DR REDDYS LABORATORIES LTD
Valuation N/A
Healthcare Risk 30 · Moderate
Price$11.90
Model IV—
P/IV—
Limited data — see page
REA
Rare Earths Americas, Inc.
Valuation N/A
Basic Materials Risk 54 · Elevated
Price$10.87
Model IV—
P/IV—
Limited data — see page
REAX
Real Brokerage Inc
Valuation N/A
Real Estate Risk 33 · Moderate
Price$20.28
Model IV—
P/IV—
Market implies +7.1%/yr vs model +15.0% · below model
RELX
RELX PLC
Valuation N/A
Technology Risk 38 · Moderate
Price$34.22
Model IV—
P/IV—
Limited data — see page
RENX
RenX Enterprises Corp.
Valuation N/A
Utilities Risk 62 · High
Price$1.78
Model IV—
P/IV—
Limited data — see page
REPL
Replimune Group, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$12.92
Model IV—
P/IV—
Limited data — see page
RERE
ATRenew Inc.
Valuation N/A
Consumer Cyclical Risk 60 · High
Price$3.97
Model IV—
P/IV—
Limited data — see page
RETO
ReTo Eco-Solutions, Inc.
Valuation N/A
Industrials Risk 46 · Elevated
Price$0.39
Model IV—
P/IV—
Market implies +13.3%/yr vs model +2.0% · above model
REVB
REVELATION BIOSCIENCES, INC.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$0.96
Model IV—
P/IV—
Limited data — see page
REVBW
REVELATION BIOSCIENCES, INC.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$0.01
Model IV—
P/IV—
Limited data — see page
RFAI
RF Acquisition Corp II
Valuation N/A
Financial Services Risk 27 · Moderate
Price$30.10
Model IV—
P/IV—
Limited data — see page
RFAIR
RF Acquisition Corp II
Valuation N/A
Financial Services Risk 33 · Moderate
Price$0.15
Model IV—
P/IV—
Limited data — see page
RFAIU
RF Acquisition Corp II
Valuation N/A
Financial Services Risk 49 · Elevated
Price$47.01
Model IV—
P/IV—
Limited data — see page
RFAM
RF Acquisition Corp III
Valuation N/A
Financial Services Risk 58 · Elevated
Price$9.98
Model IV—
P/IV—
Limited data — see page
RFAMR
RF Acquisition Corp III
Valuation N/A
Financial Services Risk 49 · Elevated
Price$0.11
Model IV—
P/IV—
Limited data — see page
RFAMU
RF Acquisition Corp III
Valuation N/A
Financial Services Risk 52 · Elevated
Price$10.01
Model IV—
P/IV—
Limited data — see page
RFI
COHEN & STEERS TOTAL RETURN REALTY FUND INC
Valuation N/A
Unknown
Price$11.01
Model IV—
P/IV—
Limited data — see page
RFIL
R F INDUSTRIES LTD
Valuation N/A
Technology Risk 43 · Elevated
Price$10.32
Model IV—
P/IV—
Market implies +33.8%/yr vs model +9.8% · above model
RFM
RiverNorth Flexible Municipal Income Fund, Inc.
Valuation N/A
Unknown
Price$13.86
Model IV—
P/IV—
Limited data — see page
RFMZ
RiverNorth Flexible Municipal Income Fund II, Inc.
Valuation N/A
Unknown
Price$12.65
Model IV—
P/IV—
Limited data — see page
RGC
Regencell Bioscience Holdings Ltd
Valuation N/A
Healthcare Risk 34 · Moderate
Price$5.64
Model IV—
P/IV—
Limited data — see page
RGEN
REPLIGEN CORP
Valuation N/A
Healthcare Risk 38 · Moderate
Price$165.18
Model IV—
P/IV—
Limited data — see page
RGLD
ROYAL GOLD INC
Valuation N/A
Financial Services Risk 59 · Elevated
Price$252.28
Model IV—
P/IV—
Limited data — see page
RGNT
REGENTIS BIOMATERIALS LTD.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.89
Model IV—
P/IV—
Limited data — see page
RGNX
REGENXBIO Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$8.53
Model IV—
P/IV—
Market implies +57.1%/yr vs model +2.0% · above model
RGT
ROYCE GLOBAL TRUST, INC.
Valuation N/A
Unknown
Price$14.61
Model IV—
P/IV—
Limited data — see page
RGTI
Rigetti Computing, Inc.
Valuation N/A
Technology Risk 41 · Elevated
Price$15.27
Model IV—
P/IV—
Market implies +143.8%/yr vs model +2.0% · above model
RGTIW
Rigetti Computing, Inc.
Valuation N/A
Technology Risk 31 · Moderate
Price$6.43
Model IV—
P/IV—
Market implies +63.2%/yr vs model +15.0% · above model
RIBB
Ribbon Acquisition Corp.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$8.10
Model IV—
P/IV—
Limited data — see page
RIBBR
Ribbon Acquisition Corp.
Valuation N/A
Financial Services Risk 36 · Moderate
Price$0.30
Model IV—
P/IV—
Limited data — see page
RIBBU
Ribbon Acquisition Corp.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$14.90
Model IV—
P/IV—
Limited data — see page
RIOT
Riot Platforms, Inc.
Valuation N/A
Financial Services Risk 48 · Elevated
Price$21.47
Model IV—
P/IV—
Market implies +50.5%/yr vs model +32.0% · above model
RIV
RIVERNORTH OPPORTUNITIES FUND, INC.
Valuation N/A
Unknown
Price$10.77
Model IV—
P/IV—
Limited data — see page
RIVN
Rivian Automotive, Inc. / DE
Valuation N/A
Consumer Cyclical Risk 37 · Moderate
Price$16.03
Model IV—
P/IV—
Market implies +84.1%/yr vs model +8.0% · above model